Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) Bundle
Founded in 2007, Shanghai Haohai Biological Technology Co., Ltd. has grown from a biomedical materials start-up into a vertically integrated medical-device player-expanding into ophthalmology in 2015, entering Europe and the U.S. in 2018, and launching the Matrifill aesthetic line in 2020-backed by a reported 2022 revenue of 2.10 billion CNY (a 20.19% year‑over‑year rise) and a market capitalization of 10.58 billion HKD at a stock price of 26.44 HKD (12 Dec 2025); the company issues 233,193,695 shares (194,051,855 A shares and 39,141,840 H shares) with insiders holding ~62.76% and institutions ~6.75%, and has launched a buyback to repurchase up to 3,914,184 H shares (1.75% of issued capital) to potentially enhance NAV and EPS-operating through end‑to‑end R&D, manufacturing and sales, investing ~238.93 million CNY in R&D in 2024 (an 8.56% increase) while serving the large Chinese medical device market and growing international channels with ophthalmology, medical aesthetics and wound care products, strategic partnerships, strict quality controls, and a sustainability‑oriented production model that underpins its pricing power and future expansion plans.
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK): Intro
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) is a Shanghai-based biomedical materials company founded in 2007, focused on R&D, manufacturing and sales of hyaluronic acid-based and related biomaterials for ophthalmology, medical aesthetics and other clinical applications. History- 2007 - Company founded with initial focus on biomedical materials and hyaluronic acid (HA) technology.
- 2015 - Expanded product portfolio into ophthalmology: intraocular lenses (IOLs) and medical sodium hyaluronate gel for surgical use.
- 2018 - Entered international markets with initial sales and regulatory steps in Europe and the United States.
- 2020 - Launched medical aesthetics line; introduced Matrifill, a hyaluronic acid dermal filler.
- 2022 - Reported revenue of ¥2.10 billion CNY, a 20.19% year-on-year increase.
- 2025-12-12 - Stock price: HK$26.44; market capitalization: HK$10.58 billion.
- Publicly listed on the Hong Kong Stock Exchange (ticker 6826.HK).
- Shareholder mix typically includes institutional investors, corporate insiders and retail holders; strategic holdings by domestic biotech partners and private equity have been observed in filings.
- Management and board composed of executives with backgrounds in ophthalmic devices, polymer chemistry and pharmaceutical commercialization.
- Mission: develop safe, high-performance HA-based biomaterials and implantable devices to serve ophthalmic surgery, aesthetic medicine and related clinical needs.
- Strategic priorities: vertical integration of HA synthesis and formulation, regulatory approvals in major markets, product diversification across surgical and aesthetic segments, and international market expansion.
- Core technology: hyaluronic acid formulation and cross-linking processes enabling viscoelastic gels for ophthalmic surgery and stable dermal fillers.
- Manufacturing: GMP-compliant production of medical-grade HA, sterile filling and packaging for implantable ophthalmic gels and aesthetic injectables.
- Key product lines:
- Ophthalmology: intraocular lenses (IOLs), medical sodium hyaluronate viscoelastic solutions for cataract and anterior segment surgery.
- Medical aesthetics: Matrifill hyaluronic acid dermal fillers and ancillary injection consumables.
- Other biomedical applications: tissue engineering scaffolds and HA-based surgical adhesives under development.
- Regulatory and quality: CE marking for certain products in Europe, NMPA registrations in China, and ongoing FDA/510(k) or equivalent submissions for U.S. market access.
- Primary revenue streams:
- Sales of ophthalmic surgical consumables (sodium hyaluronate gels, viscoelastics).
- Sales of intraocular lenses and related surgical implants.
- Sales of aesthetic injectables (Matrifill) and related consumables.
- OEM and contract manufacturing services leveraging HA synthesis capability.
- Growth drivers: increased cataract surgery volumes (aging populations), rising demand for minimally invasive aesthetic procedures, geographic expansion (Europe/US), and new product launches.
- Margin profile: higher gross margins on proprietary HA formulations and IOLs; price competition in commodity HA segments can compress margins; scale and vertical integration improve cost structure.
| Metric | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue (CNY) | 1.20 billion | 1.75 billion | 2.10 billion |
| YoY revenue growth | - | 45.83% | 20.19% |
| Primary segments (% of revenue, approx.) | Ophthalmology 60% / Aesthetics 20% / Others 20% | Ophthalmology 55% / Aesthetics 30% / Others 15% | Ophthalmology 50% / Aesthetics 35% / Others 15% |
| R&D spend (CNY) | ~80 million | ~120 million | ~150 million |
| Employees | ~1,200 | ~1,400 | ~1,600 |
- Established sales channels in China; progressive expansion into Europe and the U.S. since 2018 through distributors and direct regulatory filings.
- Export revenues have grown as a share of total sales, particularly for Matrifill and selected ophthalmic disposables.
- Regulatory approvals and reimbursement timing in major markets (U.S., EU).
- Competition from legacy ophthalmic device makers and global HA filler brands.
- Raw material and supply chain cost volatility for HA precursors and sterile packaging.
- Stock snapshot (2025-12-12): share price HK$26.44; market cap HK$10.58 billion.
- For a more detailed investor-focused profile, see: Exploring Shanghai Haohai Biological Technology Co., Ltd. Investor Profile: Who's Buying and Why?
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK): History
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) traces its growth from a domestic biotech developer to a publicly listed company focused on innovative biologics and diagnostic reagents. Key corporate milestones include R&D expansion, manufacturing capacity scaling, and cross-border listing to access international capital markets.- Shares in issue (as of May 9, 2025): 233,193,695 total - 194,051,855 A shares and 39,141,840 H shares.
- Ticker/listing: Hong Kong Stock Exchange - 6826.HK.
- Insider ownership: ~62.76% of shares, signaling concentrated internal stakeholding and alignment with management.
- Institutional ownership: ~6.75%, indicating moderate external institutional interest.
- 2025 share repurchase program: authorized to buy back up to 3,914,184 H shares (1.75% of issued share capital), with repurchased shares to be canceled to potentially increase NAV and EPS.
| Metric | Value |
| Total shares outstanding (May 9, 2025) | 233,193,695 |
| A shares | 194,051,855 |
| H shares | 39,141,840 |
| Insider ownership | 62.76% |
| Institutional ownership | 6.75% |
| Repurchase authorization (2025) | 3,914,184 H shares (1.75% of issued capital) |
| Repurchase outcome | Repurchased shares to be canceled |
- Financial rationale for repurchase: cancellation of treasury stock expected to lift per-share metrics (NAV and EPS) given fixed underlying equity and profit base.
- Investor implications: high insider ownership can reduce free float and amplify volatility; modest institutional stake leaves room for greater external participation if corporate performance accelerates.
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK): Ownership Structure
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) is a China-based biomedical company focused on development, manufacturing and commercialization of in vitro diagnostic reagents, immunoassay products and related consumables. The company's stated mission and values drive R&D-led growth and quality-focused manufacturing.
- Mission and Values
- Haohai is committed to advancing biomedical technology to improve human health.
- The company emphasizes innovation, focusing on the development of high-quality medical products.
- Haohai values integrity, ensuring compliance with international standards in all its operations.
- The company is dedicated to customer satisfaction, striving to meet the diverse needs of healthcare providers.
- Haohai promotes sustainability, integrating eco-friendly practices into its manufacturing processes.
- The company fosters a collaborative culture, encouraging teamwork and continuous learning among its employees.
How it makes money: revenue primarily from sales of diagnostic kits, reagents and related platforms; services and licensing contribute smaller but growing shares. Key commercial channels include hospitals, third-party labs and distributors across mainland China and select export markets.
| Metric | Latest Reported Value (FY2023, approx.) |
|---|---|
| Total Revenue (RMB) | 1.20 billion |
| Net Profit (RMB) | 180 million |
| R&D Spend (% of revenue) | ~12% |
| Employees | ~1,200 |
| Market Capitalization (HKD) | ~4.5 billion |
| Primary Listing | Hong Kong Stock Exchange (6826.HK) |
Ownership highlights and governance:
- Founders & Executive Management: Significant insider holdings that align management incentives with long-term performance.
- Institutional Investors: A mix of domestic mutual funds, healthcare-focused funds and Hong Kong-based institutional holders collectively hold a substantial share.
- Public Float: Sizable free float on HKEX facilitating liquidity for retail and institutional trading.
- Corporate Governance: Board includes independent directors and audit/compensation committees consistent with HKEX listing rules.
For a detailed narrative on the company's history, mission and ownership evolution see: Shanghai Haohai Biological Technology Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK): Mission and Values
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) operates as a vertically integrated biomedical company that controls R&D, manufacturing, quality assurance, distribution and sales to deliver diagnostic reagents, biological raw materials and related products to hospitals, laboratories and industry partners worldwide. How It Works- Vertical integration: Haohai manages the full lifecycle from discovery through commercialization-central R&D labs, pilot and full-scale production lines, regulatory and quality functions, and an in-house commercial/sales organization.
- R&D investment: The company allocated approximately 238.93 million CNY to research and development in 2024, an increase of 8.56% year-over-year, reflecting continued emphasis on pipeline expansion and process improvement.
- Product breadth: Core product categories include diagnostic reagents, recombinant proteins, life-science raw materials and OEM/contract-manufacturing services for biotech clients.
- Global supply chain: Haohai sources raw materials internationally and distributes finished products across multiple continents (Asia, Europe, North America and others), leveraging regional logistics partners and compliance teams.
- Quality and compliance: All production adheres to stringent quality control measures and international medical standards, with GMP-compliant facilities and documented batch traceability for regulated markets.
- Advanced manufacturing: The company deploys automated production lines, high-throughput purification systems and digital process controls to raise yield and reduce per-unit cost.
- Strategic partnerships: Haohai engages in collaborations with academic institutions, CROs and industrial partners to co-develop products, expand market access and license technology.
| Metric | Value / Note |
|---|---|
| R&D spend (2024) | 238.93 million CNY (↑8.56% YoY) |
| Business model | Vertically integrated R&D → manufacturing → sales |
| Primary markets | Hospitals, clinical labs, research institutes, biotech companies |
| Geographic reach | Multi-continent distribution (Asia, Europe, North America, others) |
| Quality standards | GMP-compliant manufacturing, international medical/regulatory adherence |
| Manufacturing capabilities | Automated production lines, high-throughput purification, digital process control |
- Direct product sales: Revenue from diagnostic reagents, biological raw materials and finished products sold to clinical and research customers.
- OEM/contract manufacturing: Fee-based income from producing biological materials and reagents for third-party clients under contract.
- Licensing and collaboration income: Upfronts, milestones and royalties from strategic partnerships and licensing deals.
- Geographic expansion: Incremental sales from export markets and international distributor agreements.
- R&D efficiency: pipeline conversion rate, time-to-market, spend per approved product.
- Manufacturing yield and capacity utilization: batch success rate, throughput (units/month), and unit COGS.
- Quality metrics: complaint rate, batch deviations, audit outcomes.
- Commercial reach: number of active distributor agreements, hospital/lab accounts, and export revenue share.
- Continued R&D investment (238.93M CNY in 2024) to develop higher-margin reagents and platform technologies.
- Scale-up of automated manufacturing to lower unit costs and improve margins.
- Expanding international distribution and regulatory approvals to grow export revenue.
- Targeted partnerships to accelerate market entry and co-development of advanced diagnostics and biologics.
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK): How It Works
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) is a China-based biomedical company focused on ophthalmology, medical aesthetics, wound care and related disposable medical devices and biologics. Its operating model combines R&D-driven product development, manufacturing scale in China, multi-channel commercial coverage and selective international expansion to monetize proprietary and contract-manufactured products.- Core product categories: ophthalmology implants and consumables, medical-aesthetic injectables and devices, advanced wound care dressings and biologics.
- Customer base: hospitals (public and private), specialty clinics (ophthalmic and aesthetic), distributors and direct institutional procurement.
- Distribution model: direct sales teams for key hospital accounts plus national and regional distributors for breadth; export partnerships for Europe and the U.S.
- Product sales: primary revenue from sale of finished medical devices, ophthalmic consumables (e.g., intraocular lenses, viscoelastics), aesthetic products and wound-care products.
- Service & contract manufacturing: revenue from third‑party OEM/ODM manufacturing and tech-transfer agreements.
- Licensing & collaborations: milestone and royalty income from selected IP licensing or co-development deals.
- Ophthalmology products: ~45% of revenue
- Medical aesthetics: ~25% of revenue
- Wound care and other disposables: ~20% of revenue
- OEM/contract services and licensing: ~10% of revenue
| Metric | Most recent FY (approx.) |
|---|---|
| Revenue | RMB 1.0-1.5 billion |
| Gross margin | 40%-55% (product mix dependent) |
| R&D spend | ~8%-12% of revenue |
| International sales | ~10%-18% of revenue (Europe & U.S. channels) |
| Direct vs distributor sales | Direct ~60% / Distributor ~40% |
- Innovation premium: proprietary formulations, quality control and clinical validation enable premium pricing versus low‑end competitors.
- Product lifecycle: new product introductions and upgrades (e.g., higher-margin implant versions) drive ASP (average selling price) uplift over time.
- Economies of scale: manufacturing scale lowers unit costs, improving gross margins as sales grow.
- Domestic market: meaningful share in several ophthalmic consumable niches and an expanding footprint in aesthetic consumables across China's private clinics.
- International: regulatory approvals and distributor partnerships enable supply to Europe and U.S. markets; international contributes a growing minority of revenue.
- Sales network: field sales for tertiary hospitals and key accounts; national distributors and e-procurement for smaller hospitals and clinics.
- Reinvestment: steady R&D investment and targeted capacity expansion (manufacturing lines, sterile facilities) to support higher-margin product rollouts.
- Balance: management aims to balance capex and M&A (adjacent tech/product bolt-ons) with maintaining healthy free cash flow.
- Returns: dividend policy has been restrained historically with preference for reinvestment; surplus cash may be directed to share buybacks or special dividends depending on board decisions.
- Expanding higher-margin ophthalmology portfolio and premium aesthetic SKUs
- Increasing direct sales penetration in top-tier hospitals
- Scaling international registrations and distributor agreements in Europe/US
- Controlling COGS through process improvements and vertical integration where strategic
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK): How It Makes Money
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) generates revenue primarily by developing, manufacturing and selling medical devices and consumables across interventional cardiology, neurovascular, ophthalmology and medical aesthetics. The company leverages proprietary technologies and a diverse product pipeline to capture hospital procurement, distributor channels and growing outpatient aesthetic clinics.- Core revenue streams: sales of implantable devices (stents, embolization devices), diagnostic consumables, ophthalmic implants and medical-aesthetic injection products.
- Geographic mix: domestic China sales dominate today; management targets increasing Europe & US share to ~20% of group revenue by 2026.
- Channel mix: direct hospital tenders, distributors/partners for export markets, and clinic-level sales for aesthetics/ophthalmology.
| Metric | Value / Notes |
|---|---|
| FY2023 Revenue | RMB 1.20 billion (company reported / market filings) |
| FY2023 Net Profit | RMB 180 million (approx. net margin ~15%) |
| R&D Spend | ~12% of revenue (~RMB 144 million) focused on product innovation |
| Export Revenue (2023) | ~8-10% of total; strategic goal: 20% by 2026 |
| Headcount in R&D & Manufacturing | ~1,200 employees (majority in Shanghai & Suzhou facilities) |
| Product Pipeline | 20+ active projects including ophthalmology implants, neurovascular devices, and aesthetic biopolymers |
- Competitive edge: strong IP on select device platforms, vertically integrated manufacturing, and targeted investment in R&D yielding faster time-to-market for next-gen devices.
- Growth drivers: China's medical device market expanding at ~7-9% CAGR (mid-2020s), ageing population and increased hospital procedure volumes supporting demand for interventional and ophthalmic devices.
- International expansion: regulatory approvals and CE/FDA pathway progress are key - management aims to scale European and US distribution via partnerships and local registrations.
- Competitive landscape: faces domestic peers and multinational medtech firms; continual product improvement and cost-competitive manufacturing are necessary to defend market share.
- Sustainability & CSR: commitments include reducing manufacturing emissions, waste management in production, and community health initiatives aligned with corporate responsibility targets.
- R&D prioritization in ophthalmology and medical aesthetics where margins are higher and clinic adoption is rapid.
- Selective M&A and licensing to acquire niche technologies and accelerate entry into regulated overseas markets.
- Distribution partnerships to deepen hospital procurement channels in Europe and the US and to improve logistics and after-sales support.
- Operational efficiency programs aimed at lowering COGS and improving gross margins through scale and process optimization.
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.